CatalystMacro

Nurix beat on Q3 earnings and revenue. For a clinical-stage biotech the print is a funding and credibility marker, not the whole story, the tape will trade the pipeline catalysts from here. $NRIX

Nurix Therapeutics Q3 earnings and revenues surpassed estimates, signaling positive financial performance.

NRIX

$24.95

+5.41%

What changed

Nurix Therapeutics Q3 earnings and revenues surpassed estimates, signaling positive financial performance.

Why it matters

Nurix Therapeutics Q3 earnings and revenues surpassed estimates, signaling positive financial performance. — impact context not separately stored; see What changed.

Sources

gnews